A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Inclusion Criteria: * Signed written informed consent form voluntarily. * Histologically or cytologically documented hepatocellular carcinoma. * CNLC IIa IIb or IIIa * The main portal vein was not completely obstructed, * Child-Pugh A or B * At least one measurable lesion according to RECIST criteria * ECOG PS 0-1 * Adequate organ function * Estimated life expectancy of ≥3 months * For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent Exclusion Criteria: * Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc * For HCC lesions ≥ 10 cm in any dimension, imaging evaluation showed that there were more than 10 lesions * The main portal vein and the left and right primary branches were clogged with cancer thrombus * History of hepatic encephalopathy or liver transplantation * Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy. * Occurred arteriovenous thromboembolic events within 6 months before the first administration. * Inadequately controlled hypertension. * Attack of symptomatic congestive heart failure (LVEF\<50%); History of congenital long QT syndrome. * Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease. * Severe infections. * Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy, * Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs. * Unable to receive an enhanced CT or MRI scan of the liver.